Merck & Co., Inc. (NYSE:MRK) is one of the best affordable stocks to buy with good earnings growth. Merck & Co., Inc.

Merck & Co. is rounding out its March deal flurry with an antibody discovery pact that could be worth as much as $838 million ...

Merck's $6.7 billion Terns acquisition bolsters its oncology pipeline while reinforcing its strong margins, steadily growing ...

Merck & Co. agreed to buy Terns Pharmaceuticals Inc. for $6.7 billion, giving the multinational company access to a promising ...

In an R&D collaboration worth as much as $838 million, Merck will lean on Infinimmune to discover immune cell-directed ...

Merck & Co., Inc. (NYSE:MRK) is one of the 10 Top Stocks Fund Managers Are Loading Up On in 2026. On March 30, 2026, Merck & Co., Inc. (NYSE:MRK) announced positive Phase 3 CORALreef AddOn trial ...

Some investors and analysts believe the pharma’s $6.7 billion offer is justified given Terns’ recent stock run. Others are ...

March 30 () - Merck's oral drug reduced bad cholesterol by up to ‌64.6% in a late-stage trial, ‌the drugmaker said on Monday, ...

Merck is bulking up its portfolio ahead of its best-selling cancer drug Keytruda losing patent protection in 2028.

Merck Completes Acquisition of JSR Life Sciences’ Chromatography Business, Expanding Protein A Capabilities and Downstream ...

Relative to its peer companies, Merck KGaA has a compelling valuation from which to realize its upside potential through its ...